Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Sepsis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Zinc Therapy in Critical Illness

NCT01162109
View directory record Official record
Conditions
Severe Sepsis
Interventions
Zinc sulfate
Dietary Supplement
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 6:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Transposable Elements in Septic Immune Aging

NCT06809868
View directory record Official record
Conditions
Sepsis, Sepsis and Septic Shock, Sepsis With Multiple Organ Dysfunction (MOD), Sepsis With Acute Organ Dysfunction, Sepsis, Severe, Sepsis at Intensive Care Unit, Sepsis, Severe Sepsis and Septic Shock, Sepsis, Septic Shock
Interventions
RNA and DNA Sequencing
Genetic
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 6:00 AM EDT
Withdrawn Phase 2 Interventional

Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)

NCT01314066
View directory record Official record
Conditions
Severe Sepsis, Acute Respiratory Distress Syndrome
Interventions
Bevacizumab, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

NCT01598831
View directory record Official record
Conditions
Severe Sepsis, Coagulopathy
Interventions
ART-123, Placebo
Drug
Lead sponsor
Asahi Kasei Pharma America Corporation
Industry
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 22, 2026, 6:00 AM EDT
Completed No phase listed Observational

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University

NCT04353388
View directory record Official record
Conditions
Sepsis, Adult Disease, Severe Sepsis, Emergency Department
Interventions
CBC-DIFF Monocyte Volume Width Distribution (MDW)
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LIPIDS-P Trial Phase I/II Trial

NCT03405870
View directory record Official record
Conditions
Sepsis, Severe, Septic Shock
Interventions
Smoflipid
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 22, 2026, 6:00 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Sepsis in Children - IMPRESS-C

NCT02598674
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions
Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 3 Interventional

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

NCT00334828
View directory record Official record
Conditions
Severe Sepsis
Interventions
eritoran tetrasodium, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 22, 2026, 6:00 AM EDT
Enrolling by invitation No phase listed Observational

Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol

NCT05304728
View directory record Official record
Conditions
Severe Sepsis, Severe Sepsis Without Septic Shock
Interventions
Not listed
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
40,000 participants
Timeline
2021 – 2026
U.S. locations
10
States / cities
Irvine, California • Augusta, Georgia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 22, 2026, 6:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Microbiome Dysfunction in Surgical Intensive Care Unit Survivors

NCT05357170
View directory record Official record
Conditions
Sepsis, Trauma Injury
Interventions
Human feces collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 110 Years
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 6:00 AM EDT
Recruiting Not applicable Interventional

Assessment for Implementation Methods in Sepsis

NCT05491941
View directory record Official record
Conditions
Sepsis Severe, Septic Shock
Interventions
Sepsis Bundle
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Jul 22, 2026, 6:00 AM EDT
Terminated No phase listed Observational

Muscle Atrophy in Patients With Severe Sepsis

NCT01717651
View directory record Official record
Conditions
Severe Sepsis, Respiratory Failure
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611
View directory record Official record
Conditions
Sepsis
Interventions
Resatorvid, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

NCT02739373
View directory record Official record
Conditions
Severe Sepsis
Interventions
BMS-986189, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 22, 2026, 6:00 AM EDT
Completed No phase listed Observational

The Role of Dysfunctional HDL in Severe Sepsis

NCT02370186
View directory record Official record
Conditions
Severe Sepsis, Septic Shock, Sepsis
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 22, 2026, 6:00 AM EDT
Not listed Not applicable Interventional

Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial

NCT02258984
View directory record Official record
Conditions
Severe Sepsis, Acute Heart Failure
Interventions
Mespere Venus 1000 Non-Invasive CVP System
Device
Lead sponsor
Mespere Lifesciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Jul 22, 2026, 6:00 AM EDT
Completed Not applicable Interventional

Predictive algoRithm for EValuation and Intervention in SEpsis

NCT03235193
View directory record Official record
Conditions
Sepsis, Septic Shock, Severe Sepsis
Interventions
Severe Sepsis Prediction, Severe Sepsis Detection
Other
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
2,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Jul 22, 2026, 6:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Measurement of Reactive Hyperemia in Critical Care

NCT01726595
View directory record Official record
Conditions
Severe Sepsis, Critical Illness
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 6:00 AM EDT
Completed No phase listed Observational

Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia

NCT00806325
View directory record Official record
Conditions
Sepsis, Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 22, 2026, 6:00 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome

NCT01992120
View directory record Official record
Conditions
Medical Knowledge, Clinical Performance
Interventions
Debriefing of high-fidelity sepsis simulation scenarios, Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Jul 22, 2026, 6:00 AM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT03821038
View directory record Official record
Conditions
Sepsis, Severe
Interventions
CYT107, Placebos
Biological · Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jul 22, 2026, 6:00 AM EDT